CAR-T Cells + Keytruda: New Immunotherapy for Pleural Mesothelioma?

immunotherapy for pleural mesothelioma

Researchers at a top US cancer center are experimenting with a new approach to immunotherapy for pleural mesothelioma – with exciting results.  The research was done at Memorial Sloan Kettering Cancer Center in New York and published in a recent issue of Cancer Discovery.  The Phase I trial is the first to treat pleural mesothelioma patients with CAR-T cell therapy and the PD-1 blocker pembrolizumab (Keytruda). Although the trial was small, 83 percent of patients lived for more than a year. Some lived for nearly two.  Malignant Mesothelioma commonly claims the lives of patients within months. This new type of immunotherapy for pleural mesothelioma could be a breakthrough in improving survival. The Challenge of Malignant Mesothelioma Scientists have known about … Continue reading CAR-T Cells + Keytruda: New Immunotherapy for Pleural Mesothelioma? »

Study May Lead to Safer Immunotherapy for Mesothelioma

immunotherapy for mesothelioma

New research conducted in Europe and at Harvard University may open the door to safer immunotherapy for mesothelioma patients.  Immunotherapy is one of the most promising approaches to fight malignant mesothelioma. But the potential side effects can be devastating.  Now, new data suggests there are ways to reduce the complications of immunotherapy for mesothelioma. The key is to target some of the white blood cells that trigger inflammation. Inflammation is the driver behind most of the serious side effects of immunotherapy.  Why Harness the Immune System? No one ever expects to contract mesothelioma. It is an extremely rare cancer. Most people who get it have spent time living or working around asbestos. Even among asbestos-exposed people, mesothelioma is rare. Scientists … Continue reading Study May Lead to Safer Immunotherapy for Mesothelioma »

Early Data Show Promise for Galinpepimut-S and Opdivo in Mesothelioma Patients

galinpepimut-s and opdivo

A combination of the immunotherapy drugs galinpepimut-S and Opdivo may give mesothelioma patients a few extra months, according to newly-released data.  The clinical data is part of an ongoing study of galinpepimut-S and Opdivo. SELLAS Life Sciences Group, the makers of galinpepimut-S, released the latest findings this week.  Although the early data is based on just four mesothelioma cases, it appears to be promising. All of the study subjects had either relapsed after chemotherapy or failed to respond at all.  These patients had a median overall survival of 35.4 weeks on the combination of galinpepimut-S and Opdivo. Typical overall survival in relapsed patients with standard care is just 7 months.  Immunotherapy with Galinpepimut-S and Opdivo Galinpepimut-S and Opdivo are both … Continue reading Early Data Show Promise for Galinpepimut-S and Opdivo in Mesothelioma Patients »

Effectiveness of Keytruda: Dutch Study Offers Clues for Prediction

effectiveness of Keytruda

A new Dutch study offers some clues that might help doctors predict the effectiveness of Keytruda (pembrolizumab) in individual mesothelioma patients.  Keytruda is the brand name for pembrolizumab. It is an immunotherapy drug called an immune checkpoint inhibitor. It helps unmask mesothelioma cells so that the immune system can find and fight them.  But the effectiveness of Keytruda is not consistent. Some patients respond well while others do not respond at all. The new study looked at how different people metabolize the drug. Understanding this could help doctors determine the best dose for each mesothelioma patient.  Pembrolizumab and its Link to Mesothelioma Survival Malignant pleural mesothelioma is a deadly form of lung cancer. Asbestos exposure is the main cause of … Continue reading Effectiveness of Keytruda: Dutch Study Offers Clues for Prediction »

Treatment with Dendritic Cells Leads to Long-Term Mesothelioma Survival in Small Studies

dendritic cells

Three small studies suggest that dendritic cells may offer a new, more promising way to fight malignant pleural mesothelioma.  Dendritic cells are immune system cells that function as messengers. They are supposed to signal T-cells to attack cancers like malignant mesothelioma. But mesothelioma cells can keep dendritic cells from doing their job. The result is that the number of activated T-cells around mesothelioma tumors stays low and the tumors keep growing.   Now, Dutch researchers studying the problem say a vaccine made from dendritic cells may hold the answer. They analyzed the results of three small dendritic cell studies. These studies included a total of 29 mesothelioma patients.  Some of the patients in these studies lived much longer than mesothelioma patients normally … Continue reading Treatment with Dendritic Cells Leads to Long-Term Mesothelioma Survival in Small Studies »

Higher PD-L1 Protein May Predict Shorter Mesothelioma Survival

PD-L1 protein

Mesothelioma patients with higher levels of the PD-L1 protein in their tumor cells have worse overall survival compared to those with lower levels. But that may not be true for patients who have immunotherapy. That news comes from a new European study of more than 200 patients. PD-L1 and its partner protein PD-1 (found in immune system cells) are popular targets for new immunotherapy drugs. But the new study aimed to find out if they impact mesothelioma survival independently of immunotherapy. The team concluded the PD-L1 protein may shorten lifespan. PD-1 does not seem to have the same effect.  Pleural Mesothelioma and the PD-L1 Protein Pleural mesothelioma is an intractable cancer of the lung lining. It often leads to poor … Continue reading Higher PD-L1 Protein May Predict Shorter Mesothelioma Survival »

Different Mesothelioma Subtypes: Gene Study Could Lead to Targeted Treatments

different mesothelioma subtypes

A group of European pathologists say the different mesothelioma subtypes have significant differences in their pattern of gene expression. Exploiting these differences could help scientists craft more effective mesothelioma treatments.  Asbestos exposure is the primary cause of mesothelioma. But doctors know that genetics play a role, too. Newly-approved immunotherapy drugs target proteins expressed by specific genes. But these drugs work much better in some mesothelioma patients than they do in others.  The new study suggests that differences in the genetic profiles of different mesothelioma subtypes could help explain why.  Immunotherapy Drugs for Mesothelioma Immunotherapy is an up-and-coming treatment approach for mesothelioma and other cancers. It harnesses the power of the person’s immune system to fight cancer.  In people with mesothelioma, … Continue reading Different Mesothelioma Subtypes: Gene Study Could Lead to Targeted Treatments »

Genetic Links to Mesothelioma Illustrated in New Interactive Model

genetic links to mesothelioma

An interactive model of protein interactions could reveal new genetic links to mesothelioma and even lead to new treatments.  The model is the brainchild of researchers in the US and India. It is a map of the thousands of protein-to-protein interactions that govern how mesothelioma cells develop, thrive, and spread.  Understanding the genetic links to mesothelioma is key to understanding who gets the disease and who does not. It is also crucial for developing new therapies aimed at manipulating the way mesothelioma cells use certain proteins.  Proteins Govern Cellular Functions Mesothelioma is a cancer of the membranes around organs. Asbestos is the main cause of mesothelioma worldwide. But only a small percentage of people who are exposed to asbestos go … Continue reading Genetic Links to Mesothelioma Illustrated in New Interactive Model »

Visualizing the Immune Profile of Mesothelioma Patients

immune profile

Researchers at MD Anderson Cancer Center in Houston have come up with a better way to analyze the immune profile of people with malignant mesothelioma.  A person’s immune profile is the unique set of immune system cells and how they are working at any given time. The functionality of immune system cells in the area right around the tumor – the tumor microenvironment or TME – is especially telling.  The system developed at MD Anderson assigns different colors to key immune system markers. They applied the color system to a sample from the microenvironment of mesothelioma tumors. The result was an image of each tmor’s immune profile. These images could help doctors determine new targets for mesothelioma treatment.  What is … Continue reading Visualizing the Immune Profile of Mesothelioma Patients »

ONCOS-102 Gets Fast Track Designation for Mesothelioma Treatment

Fast Track designation

An immunotherapy treatment called ONCOS-102 has received fast track designation from the FDA as a pleural mesothelioma therapy. Targovax is a Norweigian company that makes ONCOS-102. The company made the announcement today. It means that ONCOS-102 could be available to help people with pleural mesothelioma sooner.  Fast-track designation is for therapies with the potential to address serious medical conditions that have no good treatments. Right now, there is no cure for pleural mesothelioma and very few viable treatment options. The FDA based its decision on encouraging animal studies and early human trials of ONCOS-102.   Importance of Fast Track Designation ONCOS-102 is an experimental treatment made from a modified virus. The virus allows ONCOS-102 to overcome one of the biggest challenges … Continue reading ONCOS-102 Gets Fast Track Designation for Mesothelioma Treatment »

Get your free copy of
“Surviving Mesothelioma” Today!